Deutsche Bank lowered the firm’s price target on Medline (MDLN) to $42 from $48 and keeps a Hold rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline price target lowered to $54 from $56 at Bernstein
- Medline price target lowered to $55 from $60 at Citi
- Medline Maintained at Buy as Analyst Trims Price Target to $53 on Margin Pressures but Highlights Strong Growth Outlook
- Medline reports Q1 adjusted EPS 33c, consensus 29c
- Medline backs FY26 adjusted EBITDA view $3.5B-$3.6B